SpringWorks Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	5.45	0	0	35	0	0
Cost of Revenue	0.42	0	0	0	0	0
Gross Profit	5.03	0	0	35	0	0
Selling, General & Admin	197.55	134.55	71.79	29.47	16.69	8.59
Research & Development	150.49	146.12	101.68	51.86	42.55	9.9
Operating Expenses	348.04	280.67	173.47	81.32	59.24	18.49
Operating Income	-343.01	-280.67	-173.47	-46.32	-59.24	-18.49
Other Expense / Income	-17.91	-3.26	0.44	-0.75	-0.93	-0.68
Pretax Income	-325.1	-277.42	-173.91	-45.57	-58.31	-17.81
Net Income	-325.1	-277.42	-173.91	-45.57	-58.31	-17.81
Preferred Dividends	0	0	0	0	-7.73	0
Net Income Common	-325.1	-277.42	-173.91	-45.57	-50.58	-17.81
Shares Outstanding (Basic)	63	53	48	43	13	0
Shares Outstanding (Diluted)	63	53	48	43	13	0
Shares Change	18.45%	9.88%	12.00%	226.18%	3792.75%	-
EPS (Basic)	-5.15	-5.21	-3.59	-1.05	-3.81	-
EPS (Diluted)	-5.15	-5.21	-3.59	-1.05	-3.81	-
Free Cash Flow	-230.18	-171.76	-129.89	-32.83	-48.11	-14.46
Free Cash Flow Per Share	-3.65	-3.22	-2.68	-0.76	-3.62	-42.40
Gross Margin	92.25%	-	-	100.00%	-	-
Operating Margin	-6297.28%	-	-	-132.35%	-	-
Profit Margin	-5968.50%	-	-	-130.21%	-	-
Free Cash Flow Margin	-4225.81%	-	-	-93.81%	-	-
EBITDA	-321.78	-275.52	-172.43	-44.18	-58.11	-17.8
EBITDA Margin	-5907.55%	-	-	-126.22%	-	-
Depreciation & Amortization	3.32	1.9	1.48	1.4	0.19	0.02
EBIT	-325.1	-277.42	-173.91	-45.57	-58.31	-17.81
EBIT Margin	-5968.50%	-	-	-130.21%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).